Delivering antiviral siRNA into human T-cells: New approaches in RNAi-based HIV therapy.
The ability to block the expression of any disease-causing gene or disease-related protein highlights the potential use of RNAi technology in the therapy of 'undruggable' human diseases. However, considering the risks associated with RNAi therapy, targeting and restricting the action of siRNA to specific cells could greatly minimize toxic side effects. However, this is a major challenge, as many primary cell types are highly recalcitrant to siRNA uptake. This review discusses advances in siRNA targeting methods for human T-cells, with an emphasis on the potential use of an RNAi-based therapy for the treatment of HIV/AIDS.
Ban
Hong-Seok
HS
Hanyang University, Department of Bioengineering, 17 Haengdang-dong Seongdong-gu, Seoul 133-797, South Korea.
Lee
Sang-Kyung K
SK
Kumar
Priti
P
D000163:Acquired Immunodeficiency Syndrome / Q000235:genetics / Q000628:therapy; D000818:Animals; D018390:Gene Targeting; D005822:Genetic Vectors; D015658:HIV Infections / Q000235:genetics / Q000628:therapy*; D006801:Humans; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000009:adverse effects; D013601:T-Lymphocytes / Q000378:metabolism
D034741:RNA, Small Interfering